MedTrace Logo

Valsartan in Cardiovascular Disease With Renal Dysfunction (The V-CARD) Study

NCT00140790 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2016-02-26

No results posted yet for this study

Summary

The purpose of this study is to investigate if an angiotensin II receptor blocker, valsartan 160 mg/day is more effective to reduce the incidence of cardiovascular events as compared to 40 mg/day in patients with moderate renal dysfunction.

Conditions

Interventions

DRUG

valsartan

valsartan 40 or 160 (80) mg per day

Sponsors & Collaborators

  • Kumamoto University

    lead OTHER

Principal Investigators

  • Hisao Ogawa, MD, PhD · Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00140790 on ClinicalTrials.gov